RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo3715.2018
T1  - Chemotherapy improves survival rate in Stage 1 ovarian cancers
A1  - L. Dewick
A1  - J. Raut
A1  - V. Asher
K1  - Ovarian cancer; Stage 1; Adjuvant; Chemotherapy.
YR  - 2018
SP  - 49
AB  - <p>Purpose of Investigation: The role of adjuvant chemotherapy in Stage 1 ovarian cancer is conflicting with no clear evidence to support adjuvant chemotherapy versus observation alone. The authors sought to establish the survival benefit of adjuvant chemotherapy in all Stage 1 ovarian cancers. Materials and Methods: Retrospective data including age, stage, grade, histology, RMI, and chemotherapy status on all patients undergoing treatment for Stage 1 ovarian cancer between May 2003 and November 2013 at Royal Derby Hospital was collected. Results: Eighty-nine cases of Stage 1 ovarian cancer were included. A total of 73 patients (84.88%) received adjuvant chemotherapy while 13 (15.12%) did not. The patients receiving adjuvant chemotherapy had a median overall survival (OS) of 108 months (CI 99.07−118.33) while the median OS for the patients who did not receive any adjuvant treatment was 63.71 months (CI 43.06−83.35) p = 0.003. Conclusion: Adjuvant chemotherapy significantly improves OS in Stage 1 ovarian cancer patients.</p>